Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BIIB Biogen Inc
- Stocks
- Healthcare
- NASDAQ: BIIB
Price (delayed)
$123.16
Market cap
$18.05B
P/E Ratio
12.12
Dividend/share
N/A
EPS
$10.16
Enterprise value
$22.07B
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Highlights
The P/E is 34% below the 5-year quarterly average of 18.4 and 34% below the last 4 quarters average of 18.4
The equity has grown by 12% YoY
Biogen's net income has increased by 27% YoY but it has decreased by 9% QoQ
The EPS has grown by 26% YoY but it has contracted by 9% from the previous quarter
Key stats
What are the main financial stats of BIIB
Market
Valuations
Earnings
Shares outstanding
146.53M
Market cap
$18.05B
Enterprise value
$22.07B
Price to earnings (P/E)
12.12
Price to book (P/B)
1.06
Price to sales (P/S)
1.83
EV/EBIT
12.59
EV/EBITDA
8.75
EV/Sales
2.25
Revenue
$9.82B
Gross profit
$7.42B
Operating income
$1.75B
Net income
$1.48B
EBIT
$1.75B
EBITDA
$2.52B
Free cash flow
$2.38B
Per share
Balance sheet
Liquidity
EPS
$10.16
EPS diluted
$10.13
Free cash flow per share
$16.32
Book value per share
$115.99
Revenue per share
$67.19
TBVPS
$81.94
Total assets
$28.03B
Total liabilities
$11.05B
Debt
$6.62B
Equity
$16.98B
Working capital
$2.33B
Debt to equity
0.39
Current ratio
1.44
Quick ratio
0.87
Net debt/EBITDA
1.6
Margins
Efficiency
Dividend
EBITDA margin
25.7%
Gross margin
75.6%
Net margin
15.1%
Operating margin
17.9%
Return on assets
5.3%
Return on equity
9%
Return on invested capital
15%
Return on capital employed
7.7%
Return on sales
17.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BIIB stock price
How has the Biogen stock price performed over time
Intraday
-1%
1 week
5.43%
1 month
6.94%
1 year
-45.34%
YTD
-19.46%
QTD
-10%
Financial performance
How have Biogen's revenue and profit performed over time
Revenue
$9.82B
Gross profit
$7.42B
Operating income
$1.75B
Net income
$1.48B
Gross margin
75.6%
Net margin
15.1%
BIIB's operating income is up by 32% year-on-year but it is down by 8% since the previous quarter
Biogen's operating margin has increased by 31% YoY but it has decreased by 9% from the previous quarter
Biogen's net income has increased by 27% YoY but it has decreased by 9% QoQ
Biogen's net margin has increased by 25% YoY but it has decreased by 11% from the previous quarter
Price vs fundamentals
How does BIIB's price correlate with its fundamentals
Growth
What is Biogen's growth rate over time
Valuation
What is Biogen stock price valuation
P/E
12.12
P/B
1.06
P/S
1.83
EV/EBIT
12.59
EV/EBITDA
8.75
EV/Sales
2.25
The P/E is 34% below the 5-year quarterly average of 18.4 and 34% below the last 4 quarters average of 18.4
The EPS has grown by 26% YoY but it has contracted by 9% from the previous quarter
BIIB's price to book (P/B) is 63% lower than its 5-year quarterly average of 2.9 and 34% lower than its last 4 quarters average of 1.6
The equity has grown by 12% YoY
The stock's price to sales (P/S) is 45% less than its 5-year quarterly average of 3.3 and 32% less than its last 4 quarters average of 2.7
Efficiency
How efficient is Biogen business performance
The ROIC has soared by 79% YoY
The ROS has grown by 31% YoY but it has contracted by 9% from the previous quarter
Biogen's return on assets has increased by 20% YoY but it has decreased by 10% QoQ
The ROE has grown by 14% YoY but it has contracted by 12% from the previous quarter
Dividends
What is BIIB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BIIB.
Financial health
How did Biogen financials performed over time
The total assets is 154% more than the total liabilities
The current ratio has contracted by 31% YoY but it has grown by 7% from the previous quarter
The company's quick ratio rose by 13% QoQ but it fell by 8% YoY
Biogen's debt is 61% less than its equity
The debt to equity has decreased by 15% YoY and by 2.5% from the previous quarter
The equity has grown by 12% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.